A finless porpoise shot by Yang He at Yangtze River in Hubei Province, Feb. 19, 2021.
A finless porpoise shot by Yang He at Yangtze River in Hubei Province, Feb. 19, 2021.
YICHANG, China, June 01, 2023 (GLOBE NEWSWIRE) — Yang He, 65 years old from Yichang, Hubei Province, who has been photographing finless porpoises for 5 years has noticed a rise in population since the chemical plant has been replaced by a riverside park in Yichang, Hubei Province.
The keen photographer brought river traffic to a standstill in the Yichang section of China’s mother river when he rescued a porpoise caught up in rope and bottles on February 9, 2022, he dubbed the porpoise 209 after the date. The story of the porpoise and Yang He has now been immortalized in a video of sand paintings (see below).
The story became legend after Three Gorges Maritime Safety Administration issued an emergency order requesting the suspension of sailing of all cargo ships nearby immediately after being informed of the situation. The “pause button” was pressed on the golden waterway to save the trapped finless porpoise. The rescue team slowly approached the finless porpoise in a small boat, and it took repeated attempts for the members to work together to hold it.
Fortunately, they made it, and saved the finless porpoise. The finless porpoise is said to be the elf in the Yangtze River. From then on, 209 remembered his savior Yang He. Every time he took photos at the riverside, the porpoise would always appear. The obvious wound on its tail proved that it was the finless porpoise dubbed 209.
209 and her daughter played with each other, shot by Yang He at Yangtze River in Hubei Province, May 5, 2022
209 and her daughter played with each other, shot by Yang Heat Yangtze River in Hubei Province, May 5, 2022
Two months later, Yang He spotted 209 jumping out of the water, and he managed to capture this in a photograph. He was pleasantly surprised to find that 209 was pregnant. Later, it gave birth to a baby, and both mother and baby would meet Yang. Yang He has shared many photos of the finless porpoises on WeChat Moments, including countless “registration photos” and “family portraits” of these animals who he says ‘are as adorable as his own children’.
The area is now seeing a surge in environmental efforts and also visitors to watch these animals. Today, pods of these captivating creatures can once again be observed leaping above the water’s surface, allowing enthusiastic shutterbugs and local residents to marvel at their beauty.
Amsterdam, the Netherlands and Irvine, California, U.S. –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Masimo (NASDAQ: MASI), a global medical technology company, today announced FDA clearance allowing the activation of SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment.
Integrating the SedLine, O3® and CO2 advanced Masimo measurements into Philips high acuity IntelliVue® MX series multi-parameter monitors can help clinicians assess and monitor blood saturation in the brain (cerebral oxygenation), anesthetic sedation, and patient respiratory performance with ease, all from the same monitor. The data can also be shared between monitors. These capabilities and metrics help care providers to act decisively while also helping to lower cost of care by providing a more holistic view of the patient from one system.
“Our work with Masimo has enabled us to forge new paths in continuous monitoring,” said Christoph Pedain, General Manager, Hospital Patient Monitoring at Philips. “We’re connecting data and technologies to help arm care providers with the robust information they need to make timely, informed care decisions for their patients.”
“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike,” said Jon Coleman, President of Worldwide OEM Sales and Global Health, Masimo. “We are proud that Philips has chosen to make our innovative SedLine, O3, and NomoLine technologies available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.”
Since establishing a partnership to improve patient care, outcomes and safety in 2016, Philips and Masimo have already introduced a variety of advanced monitoring capabilities to select IntelliVue® MX-series multi-parameter monitors. Today’s announcement reveals the expansion of O3 regional oximetry capability to Philips’ latest, high acuity MX750 and MX850 patient monitors, as well as the introduction of new SedLine Brain Function Monitoring and CO2 measurement capabilities, adding versatility to Philips’ already robust portfolio of patient monitoring solutions that support clinical workflow, caregiver efficiencies, and enhanced patient care. To learn more about Philips’ ongoing collaboration with Masimo to deliver on the future of continuous monitoring, visit www.philips.com/masimo.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi (rainbow® PVi), and Oxygen Reserve Index (ORi). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris® Gateway, iSirona, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and the Masimo W1 watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
1. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
8. Estimate: Masimo data on file.
9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Colliers (NASDAQ and TSX: CIGI) released its third annual Impact Report today, highlighting progress towards realizing a more sustainable and equitable future for all. This report includes information on how Colliers is delivering resilient buildings, inclusive workplaces, and spaces that promote health and wellbeing.
Key 2022 performance highlights include:
A 10.1% reduction in scope 1 and 2 emissions per square foot
215 million square feet of green-certified properties under management
285 green certifications held by Colliers professionals
39% of Colliers’ global workforce are women
Having launched a global ESG strategy, Elevate the Built Environment in 2021, Colliers is focused on achieving key milestones toward the framework’s three pillars: environment, inclusiveness, and health and wellbeing.
“Our third annual Impact Report highlights our progress in providing innovative solutions and exceptional results to clients and creating positive impact for our people and planet,” said Jay Hennick, Global Chairman & CEO. “We will continue to accelerate the success of our people, clients and communities.”
The 2022 Global Impact Report includes baseline assessments of Colliers’ Scope 1 and 2 emissions and was produced with reference to Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB, now consolidated into the International Sustainability Standards Board), and Task Force on Climate-Related Financial Disclosure (TCFD) frameworks to ensure strong governance of Colliers’ ESG programs.
“Looking ahead this decade, we are on pace to achieve our net zero and Science-Based Targets – and help many clients do the same,” said Sean Drygas, Global Lead, ESG & Impact. “On top of our focus on climate change, putting diversity, equity, and inclusion front and center is a priority, as is promoting health and wellbeing among our workforce and through the buildings we manage.”
To find out more, read the Colliers 2022 Global Impact Report here.
About Colliers
Colliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 66 countries, our 18,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 28 years, our experienced leadership with significant inside ownership has delivered compound annual investment returns of approximately 20% for shareholders. With annual revenues of $4.5 billion and $98 billion of assets under management, Colliers maximizes the potential of property and real assets to accelerate the success of our clients, our investors and our people. Learn more at corporate.colliers.com, Twitter @Colliers or LinkedIn.
Synergy to Create Value and Ensure the Future of Exclusivity
Giuseppe Santoni
Giuseppe Santoni, Chairman and Executive President
MILAN, Italy, June 01, 2023 (GLOBE NEWSWIRE) — Giuseppe Santoni announces the appointment of Eraldo Poletto as CEO of Santoni S.p.A, starting June 2023.
Strategy and integration define the present and future of Santoni. An investment in people and expertise, which sees the transition of Giuseppe Santoni to Chairman and Executive President of the family-owned company that has been representing artisanal excellence in luxury footwear and accessories worldwide for almost 50 years.
This fundamental organizational change aims to guide the brand’s strategic development and consolidate its international relevance while maintaining a strong connection to its roots. The transformation has already begun with the implementation of an internal strategic renewal plan and the appointment of experienced managers in each department, to enhance value at all levels.
While internal transformation starts with people, Santoni also aims to provide new expertise and collaboration to its employees, creating an environment in which the company’s values are always front and center.
With an entrepreneurial spirit, innovative vision, and unwavering determination to achieve strategic objectives, Poletto will be a valuable asset for Santoni. His extensive and profound experience with prominent brands, coupled with a global perspective and strong determination, make him an ideal fit. Poletto, who is already a member of Santoni’s Board of Directors and has decades of expertise in the luxury and retail sectors, has held positions such as CEO and Brand President of footwear brand Stuart Weitzman, which is part of the New York-based Tapestry group. He has also served as CEO of renowned Italian companies such as Salvatore Ferragamo and Furla, as well as Global CEO of Diesel, owned by the OTB group.
Being well-versed in the US market aligns with Santoni’s tradition of overseas presence. Poletto has the ability to transform trends that drive the exclusive products sector worldwide into value. He combines technical expertise, global market knowledge, visionary and strategic capabilities, with a distinctly Italian taste for refined and selected production that is beloved by Santoni’s exclusive clientele.
The recently appointed Chairman and Executive President, Giuseppe Santoni, stated, “Working together with Eraldo Poletto, sharing a common goal, makes our path smoother and our objectives more easily attainable. Sharing a strategic vision means creating a path for everyone to walk confidently. We must enhance our knowledge and expand our understanding to do better and ensure continuity of excellence.”
For his part, Eraldo Poletto is ready to support the creation of reproducible standards of the highest quality, reconciling excellent craftsmanship with technology that preserves the distinctive beauty and recognizable characteristics of Santoni’s Master Craftsmen’s creations.
Eraldo Poletto
Eraldo Poletto, CEO
“Santoni is born from the originality that comes from discipline, which does not conflict with creativity; instead, it serves to further develop talent,” says Eraldo Poletto, CEO of Santoni S.p.A. “Excellence in craftsmanship, distinctiveness, as well as engineering and reproducibility of the highest quality attained, are just some of the results that make us unique and incomparable.”
KUALA LUMPUR, Malaysia, June 01, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) today announced that its wholly owned subsidiary, V Capital Real Estate Sdn Bhd (“V Capital Real Estate”) has been engaged as a consultant by Tinta Anggun Engineering Sdn Bhd (“Tinta Anggun”). This is with respect to the latter’s mixed development project known as Porto De Melaka, comprising residential and commercial units on a 9.91-acre commercial land in Melaka. The land, located next to the Melaka river mouth, fronting the sea, is about 600 metres from the famous Jonker Walk within the UNESCO Heritage Site of Melaka. Melaka, located approximately 2 hours driving distance from the capital of Malaysia, Kuala Lumpur, attracts an average of 18 million tourist arrivals to the UNESCO Heritage Site of Melaka. The site also boasts a waterfront resort living style and located next to the upcoming Melaka International Yacht Club.
V Capital Real Estate’s scope of consultancy works includes, amongst others, the successful development and execution of the development strategies for Tinta Anggun, advise on the development of capital structures of equity and debt and advise in financial analysis and project evaluation.
The entire Porto De Melaka project, with a RM600 million (approximately USD130 million) gross development value (“GDV”), comprises one 241-room hotel, 1 block of serviced suite of 140 studio units and another 4 blocks of serviced apartments comprising 342 units. V Capital Real Estate’s consultancy works will focus on 3 of the 4 serviced apartments and the 241-room hotel, with a cumulative GDV of RM400 million (approximately USD87 million). The consultancy fee in turn shall be 20% of any revenue generated from this portion of the development during the 5-year term of the consultancy.
Tinta Anggun believes there is currently significant demand for residential development in Melaka and expects occupancy rates to be high given the location of this development which is in the main population centre of the Melaka state. Demand would be well supported by the state of Melaka’s mean monthly household gross income of RM7,186 (approximately USD1,560) in 2020, based on data by Department of Statistics Malaysia, which is higher than Malaysia’s overall mean monthly household gross income of RM7,089 (approximately USD1,540).
“I am humbled that our consultancy reputation is taking traction amongst the developers. Here, we would like to thank Tinta Anggun for giving us the opportunity to be part of this development which will undoubtedly play its part in sustaining the state’s economic growth, as economies continue to sail further away from the pandemic storm into a new post Covid era,” said Dato’ Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.
About VCI Global Limited
VCI Global is a multi-disciplinary consulting group with key advisory practices in the areas of business and technology. The Company provides business and boardroom strategy services, investor relation services, and technology consultancy services. Its clients range from small-medium enterprises and government-linked agencies to publicly traded companies across a broad array of industries. VCI Global operates solely in Malaysia, with clients predominantly from Malaysia, but also serves some clients from China, Singapore, and the US.
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of Coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.
CONTACT INFORMATION:
Issued by Imej Jiwa Communications Sdn Bhd on behalf of VCI Global Limited
For media queries, please contact:
BANGKOK, Thailand and NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — The Stock Exchange of Thailand (SET) has successfully launched its new trading system, together with market data distribution and market surveillance systems, based on Nasdaq (Nasdaq: NDAQ) technology. All systems are running seamlessly and operating at full efficiency in line with international standards and best practice. This newly developed state-of-the-art solution will support increasing transaction volumes and a variety of innovative investment products, whilst further enhancing the trust and integrity of the market.
This implementation marks a significant milestone in the ongoing development of the modern Thai capital market, established to promote economic growth and stability, and to develop people’s standard of living. Today, SET has the highest liquidity among ASEAN exchanges, a position the exchange has held for more than 10 years. In 2022, capital raised through IPOs totaled 3.46 billion USD, the highest in ASEAN and the fourth-largest in Asia, following China, South Korea, and India. 26 listed companies are members of Dow Jones Sustainability Indices, reflecting the leading role SET is playing helping to drive institutional capital to sustainable businesses.
SET President Pakorn Peetathawatchai said that on May 8, 2023, SET and Thailand Futures Exchange PCL (TFEX) inaugurated the new trading system, as well as the data distribution system and the market surveillance system, using the most advanced technology and innovation, developed in collaboration with Nasdaq, a world leader in market infrastructure technology. Notably, the new systems have achieved a smooth transition, enabling increase in efficiency, faster order management, while being able to support the increasing volume of transactions in the future and the development of a variety of investment products with innovations for both domestic and foreign investors, in line with the SET vision “To Make the Capital Market ‘Work’ for Everyone”.
“The new system implementation is an upgrade of the core operating system that is the heart of the Thai capital market, making it more efficient and flexible, ready to support the development of the capital market in the future. Significantly, this system has world-class and standardized connectivity as utilized by leading exchanges globally. This success will not be possible without all parties involved consisting of regulatory entities, member companies, system developers, and related entities that have helped support, develop and test the system continuously until the launch of this new system, another milestone for the development of the Thai capital market for future sustainable growth,” added Pakorn.
Nasdaq Executive Vice President and Head of Marketplace Technology, Roland Chai said, “The successful launch across a broad range of Nasdaq’s solutions reflects the benefits of an integrated approach to upgrading technology infrastructure, and a clear strategy to meet the evolving demands of the market. Global capital markets are increasingly demanding resilient and robust technology, capable of withstanding ever-greater volatility and volume. Well-functioning, trusted markets are critical to inclusive growth and prosperity, and we are pleased support the ongoing development of SET as it serves the Asian market.”
“The technology has been implemented in partnership with Nasdaq, providing an efficient, robust, and fair platform to facilitate trading across a broad spectrum of asset classes. It also leverages Nasdaq’s Market Surveillance Technology, which is widely used by regulators and exchanges globally, the company’s Index Calculation Technology, which enables providers to calculate and disseminate indices across different asset classes, currencies, sectors, and geographic regions, and Pre-trade Risk Management service, a low-latency risk solution for trading and sponsored access clients,” added Roland.
About SET
The Stock Exchange of Thailand (SET) is among the most liquid exchanges in Asia, providing a full range of investment products including equities, derivatives, as well as world-class trading, post-trade infrastructure/technology services. Going forward, SET’s vision “To Make the Capital Market ‘Work’ for Everyone” is aligned with the aim to support strong economic growth and competitiveness. Globally and regionally, SET has also actively coordinated with other exchanges to boost investment opportunities and capital market growth potential. Moreover, SET puts strong emphasis on sustainable growth by promoting listed companies’ business models that care for environmental, social and governance (ESG) practices.
About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
The partnership includes comprehensive Complaints Resolution Official (CRO) training on the Air Carrier Access Act (ACAA), MedLink in-flight medical support, and Passenger Fit-to-Fly support.
Phoenix, Arizona, May 31, 2023 (GLOBE NEWSWIRE) — MedAire, a global provider of in-flight medical and aviation security solutions, is pleased to announce a new partnership with STARLUX Airlines, Taiwan’s rapidly growing international airline. The partnership includes comprehensive Complaints Resolution Official (CRO) training on the Air Carrier Access Act (ACAA), MedLink in-flight medical support, and Passenger Fit-to-Fly support.
“STARLUX Airlines is committed to providing a premium service to our passengers while ensuring their safety and comfort. Partnering with MedAire enables us to achieve this goal while maintaining compliance with international regulations,” said Brian Lin, Chief Corporate Safety Officer of STARLUX Airlines. “MedAire’s expertise in training and medical support services makes them the perfect fit for our expanding operations.”
The partnership commenced in December 2022 with in-person meetings and workshops in Taipei, where MedAire demonstrated its ability to meet STARLUX’s needs and improve operational efficiency. In addition, MedAire’s ACAA/CRO Train-the-Trainer program was instrumental in preparing STARLUX for the recent launch of its Taipei-Los Angeles route.
Bill Dolny, CEO of MedAire, said, “We are thrilled to partner with STARLUX Airlines, a forward-thinking and ambitious airline that shares our commitment to safety and quality. Our collaboration ensures STARLUX complies with ACAA regulations on top of providing exceptional in-flight medical emergency service to their passengers.”
MedAire will provide STARLUX Airlines access to MedLink delivered in Chinese, offering local language capabilities and ensuring seamless support across all services. In addition, MedAire’s commitment to quality and safety bolsters STARLUX’s reputation.
About MedAire
MedAire is a leading provider of in-flight medical and aviation security solutions for airlines, private aviation companies, and corporate flight departments worldwide. With an extensive network of professionals and facilities, MedAire offers comprehensive support to ensure the safety and well-being of passengers and crew members.
About STARLUX Airlines
Founded in 2018, STARLUX is a luxury airline based in Taipei now serving 16 Asian destinations: Tokyo, Osaka, Fukuoka, Okinawa, Sapporo, Sendai, Macau, Penang, Kuala Lumpur, Bangkok, Singapore, Ho Chi Minh City, Da Nang, Hanoi, Manila, and Cebu. STARLUX also operates flights between Taipei and Los Angeles, providing convenient transfers for passengers traveling between Asia and North America via Taipei, and is dedicated to providing exquisite services and the utmost comfort for each passenger to enjoy an unforgettable journey. The STARLUX fleet consists of three types of new-generation Airbus aircraft—A321neo, A330neo, and A350—to provide the finest and eco-friendly journeys.
Up to an Additional $46.2 Million Available Through Warrant Exercise
Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2 million in gross proceeds.
The financing is led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company’s Chief Executive Officer and Founder, Todd R. Nelson, PhD.
Under the terms of the Redeemable Convertible Preferred Stock and Warrant Purchase Agreement, immediately following the closing of the financing, Paul Meister, a partner at Novalis LifeSciences LLC, will be appointed to the Company’s board of directors, increasing the size of its board of directors from seven to eight.
“We are pleased to announce this financing led by Novalis LifeSciences LLC with strong support from existing investors,” shared Todd R. Nelson, CEO and Founder of Telesis Bio. “Paul Meister’s tenure in the industry as a veteran executive and board member at notable companies such as Syneos Health, Fisher Scientific and ThermoFisher Scientific, will be a valuable asset to the shareholders of Telesis Bio as we seek to increase shareholder value and approach profitability in the 2024 timeframe.”
“The company’s innovative BioXp automation solutions are still in the early stages of adoption within targeted discovery workflows including biologics, cell and gene therapy and genome engineering. The value proposition to researchers will only continue to increase as the demands within the multi-omics and synthetic biology markets continues,” stated Paul Meister. “I am grateful for the opportunity to join this esteemed board of directors and support the Company’s vision for the BioXp platform.”
“While we believe strongly in our ability to grow our BioXp installed base and are confident that we can achieve our long-term revenue and profitability goals, we are adjusting expectations for the company’s financial performance for the remainder of 2023, as we continue to see challenging headwinds that may impact our revenue results,” Nelson shared. “We now anticipate full year revenue for the company to be approximately $35 million and operating expenses, including non-cash and one-time charges to be approximately $55 million. Gross margin expectations of approximately 57% remain unchanged.”
The Company intends to use the proceeds from the financing for general corporate purposes. The financing is expected to close on June 2, 2023, subject to the satisfaction of customary closing conditions.
Please refer to the Company’s Form 8-K to be filed with the Securities and Exchange Commission for the complete terms of the financing.
THIS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITY. THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR ANY STATE THEREOF ABSENT REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN APPLICABLE EXEMPTION FROM REGISTRATION REQUIREMENTS.
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
About Novalis LifeSciences LLC
Novalis LifeSciences LLC is a boutique investment and advisory firm for the Life Science industry. With a team of experienced operating executives from the industry, Novalis funds and advises visionary Life Science entrepreneurs. For more information visit www.novalislifesciences.com.
Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance, the completion, timing and size of the financing, the anticipated use of proceeds from the financing, as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (SEC) on March 22, 2023, as amended on May 17, 2023 and in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet
